skip to main content
Show Results with:

An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227)

Hellmann, Matthew et al.

Journal for immunotherapy of cancer. Volume 3:Issue 2 (2015); pp 1-2 -- BioMed Central

Online access

Searching Remote Databases, Please Wait